Since a germline mutation of the MLH1 promoter is configured as a rare event, in the absence of a personal or family history strongly suggestive of a hereditary process, for which a genetic analysis would be carried out on the promoter, the methylation of the promoter is considered a fairly reliable indicator of sporadic cancer (19). This evidence concerns the gene MLH1 and cancer.